Cargando…

Plasma Rivaroxaban Level in Patients With Early Stages of Chronic Kidney Disease—Relationships With Renal Function and Clinical Events

Introduction Drug accumulation of rivaroxaban is a concern in patients with chronic kidney disease (CKD). Data regarding the plasma rivaroxaban levels in early CKD patients and its relationship with clinical events is lacking. Methods Early CKD patients (Stage 1–3) with atrial fibrillation who recei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sin, Chun-Fung, Wong, Ka-Ping, Wong, Hoi-Man, Siu, Chung-Wah, Yap, Desmond Y. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157352/ https://www.ncbi.nlm.nih.gov/pubmed/35662694 http://dx.doi.org/10.3389/fphar.2022.888660

Ejemplares similares

Plasma apixaban levels in Chinese patients with chronic kidney disease—Relationship with renal function and bleeding complications
por: Sin, Chun-fung, et al.
Publicado: (2022)

Influence of ABCB1 Gene Polymorphism on Rivaroxaban Blood Concentration and Hemorrhagic Events in Patients With Atrial Fibrillation
por: Wang, Yan, et al.
Publicado: (2021)

The discovery of rivaroxaban: translating preclinical assessments into clinical practice
por: Kubitza, Dagmar, et al.
Publicado: (2013)

Impact of contrast-induced acute kidney injury on long-term major adverse cardiovascular events and kidney function after percutaneous coronary intervention: insights from a territory-wide cohort study in Hong Kong
por: Ng, Andrew Kei-Yan, et al.
Publicado: (2021)

Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect
por: Ing Lorenzini, Kuntheavy, et al.
Publicado: (2016)

Statin Therapy for Hyperlipidemic Patients With Chronic Kidney Disease and End-Stage Renal Disease: A Retrospective Cohort Study Based on 925,418 Adults in Taiwan
por: Sung, Fung-Chang, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Rivaroxaban in Chinese Patients With Stable Cardiovascular Disease
por: Feng, Tianyu, et al.
Publicado: (2022)

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
por: Wang, Zhi, et al.
Publicado: (2023)

Selective Estrogen Receptor Modulator-Like Activities of Herba epimedii Extract and its Interactions With Tamoxifen and Raloxifene in Bone Cells and Tissues
por: Zhou, Liping, et al.
Publicado: (2021)

Bone Protective Effects of Danggui Buxue Tang Alone and in Combination With Tamoxifen or Raloxifene in vivo and in vitro
por: Zhou, Li-Ping, et al.
Publicado: (2018)

Sequential Therapy of Nadroparin and Rivaroxaban in the Initial Treatment of Patients With Acute Pulmonary Embolism
por: Xiong, Wei, et al.
Publicado: (2022)

Rivaroxaban in heart failure patients with left ventricular thrombus: A retrospective study
por: Zhang, Qian, et al.
Publicado: (2022)

Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis
por: Chen, Can, et al.
Publicado: (2021)

Evaluation of Herb–Drug Interaction Between Danshen and Rivaroxaban in Rat and Human Liver Microsomes
por: Wang, Xu, et al.
Publicado: (2022)

Single and Repeated Doses of EGb 761(®) do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects
por: Hoerr, Robert, et al.
Publicado: (2022)

Corrigendum: Evaluation of herb–drug interaction between Danshen and rivaroxaban in rat and human liver microsomes
por: Wang, Xu, et al.
Publicado: (2022)

Combination of Wogonin and Artesunate Exhibits Synergistic anti-Hepatocellular Carcinoma Effect by Increasing DNA-Damage-Inducible Alpha, Tumor Necrosis Factor α and Tumor Necrosis Factor Receptor-Associated Factor 3-mediated Apoptosis
por: Chen, Minting, et al.
Publicado: (2021)

Prediction of Rivaroxaban-Rifampin Interaction After Major Orthopedic Surgery: Physiologically Based Pharmacokinetic Modeling and Simulation
por: Xu, Rui-juan, et al.
Publicado: (2021)

Icariin, but Not Genistein, Exerts Osteogenic and Anti-apoptotic Effects in Osteoblastic Cells by Selective Activation of Non-genomic ERα Signaling
por: Ho, Ming-Xian, et al.
Publicado: (2018)

Quantitative Systems Pharmacology Model-Based Predictions of Clinical Endpoints to Optimize Warfarin and Rivaroxaban Anti-Thrombosis Therapy
por: Hartmann, Sonja, et al.
Publicado: (2020)

The Impact of Dabigatran and Rivaroxaban on Variation of Platelet Activation Biomarkers and DRT Following Percutaneous Left Atrial Appendage Closure
por: Li, Xiaoye, et al.
Publicado: (2021)

A case report of tumor lysis syndrome after stage-one ALPPS
por: Cheung, Ho Hung, et al.
Publicado: (2022)

Evaluation of Remote Pharmacist-Led Outpatient Service for Geriatric Patients on Rivaroxaban for Nonvalvular Atrial Fibrillation During the COVID-19 Pandemic
por: Li, Xiaoye, et al.
Publicado: (2020)

International Normalized Ratio as a Screening Test for Assessment of Anticoagulant Activity for Patients Treated With Rivaroxaban or Apixaban: A Pilot Study
por: Ofek, Fanny, et al.
Publicado: (2019)

Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study
por: Grymonprez, Maxim, et al.
Publicado: (2023)

Is Danggui Safe to be Taken by Breast Cancer Patients?—A Skepticism Finally Answered by Comprehensive Preclinical Evidence
por: Yue, Grace Gar-Lee, et al.
Publicado: (2019)

The Relationship of Pyroptosis-Related Genes, Patient Outcomes, and Tumor-Infiltrating Cells in Bladder Urothelial Carcinoma (BLCA)
por: Xie, Ruiyan, et al.
Publicado: (2022)

Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study
por: Sennesael, Anne-Laure, et al.
Publicado: (2018)

Lipidomic Analysis Reveals the Protection Mechanism of GLP-1 Analogue Dulaglutide on High-Fat Diet-Induced Chronic Kidney Disease in Mice
por: Yeung, Martin Ho Yin, et al.
Publicado: (2022)

Benefits and Harms of Low-Dose Rivaroxaban in Asian Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-World Studies
por: Qian, Jun, et al.
Publicado: (2021)

Clinical Efficacy and Safety Comparison of Rivaroxaban and Dabigatran for Nonvalvular Atrial Fibrillation Patients Undergoing Percutaneous Left Atrial Appendage Closure Operation
por: Li, Xiaoye, et al.
Publicado: (2021)

Analysis of Survival Benefits of Living Versus Deceased Donor Liver Transplant in High Model for End‐Stage Liver Disease and Hepatorenal Syndrome
por: Wong, Tiffany Cho‐Lam, et al.
Publicado: (2021)

The Effects of Major Depressive Disorder on the Sequential Organization of Information Processing Stages: An Event-Related Potential Study
por: Ahorsu, Daniel Kwasi, et al.
Publicado: (2020)

A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation
por: Zhao, Nan, et al.
Publicado: (2022)

Inflammation and Cardiovascular Disease Associated With Hemodialysis for End-Stage Renal Disease
por: Wang, Yinghui, et al.
Publicado: (2022)

Intravitreal vascular endothelial growth factor inhibitors did not increase the risk of end-stage renal disease in patients with biopsy-proven diabetic kidney disease based on matched study
por: Xiao, Xiang, et al.
Publicado: (2022)

Low-dose rivaroxaban: can cardiovascular events be reduced?
por: De Luca, Leonardo
Publicado: (2023)

Potentially inappropriate medication among older patients with diabetic kidney disease
por: Wang, Yuping, et al.
Publicado: (2023)

High prevalence of de novo metabolic dysfunction-associated fatty liver disease after liver transplantation and the role of controlled attenuation parameter
por: Mak, Lung-Yi, et al.
Publicado: (2023)

Impact of Healthcare Associated Infections on Survival and Treatment Outcomes Among End Stage Renal Disease Patients on Renal Replacement Therapy
por: Abbasi, Saad Hanif, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ia1d3ojlklabo78bbf2c5pui1s